AgingResearch.NewsJoin free

Eikonizo Therapeutics

CompanyUnited States

Wikidata

Eikonizo Therapeutics develops 2 assets, the furthest in human trials ([18F]EKZ-001). Mostly small molecule acting on HDAC6; based in the United States.

2
Assets
Furthest stage
Human trials
Raised
US$2.4m
0
Trials
0
Signals

Pipeline

2

  • [18F]EKZ-001

    Human trials

  • EKZ-102

    Brain-penetrant HDAC6 inhibitor designed to achieve neuroprotection.

    Preclinical, Small molecule, HDAC6, amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants2
  • People18
  • Similar companies6

Intelligence